Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment

被引：28
|
作者：
Guo, Yelei [1 ]
Feng, Kaichao [2 ]
Tong, Chuan [1 ]
Jia, Hejin [2 ]
Liu, Yang [3 ]
Wang, Yao [1 ]
Ti, Dongdong [1 ]
Yang, Qingming [2 ]
Wu, Zhiqiang [1 ]
Han, Weidong [1 ,2 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Mol Biol & Immunol, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Dept Biotherapeut, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Hematol, Beijing, Peoples R China
来源：
CELLULAR & MOLECULAR IMMUNOLOGY | 2020年 / 17卷 / 04期
基金：
中国国家自然科学基金;
关键词：
RECEPTOR; CD38;
D O I：
10.1038/s41423-019-0355-5
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：430 / 432
页数：3
相关论文
共 50 条
  • [21] CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
    Sun, Yao
    Su, Yongfeng
    Wang, Yizhi
    Liu, Na
    Li, Yuhang
    Chen, Jianlin
    Qiao, Zhuoqing
    Niu, Jingwen
    Hu, Jiangwei
    Zhang, Bin
    Ning, Hongmei
    Hu, Liangding
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [22] Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
    Yang, Tingting
    Dong, Yetian
    Zhang, Mingming
    Feng, Jingjing
    Fu, Shan
    Xiao, Pingnan
    Hong, Ruimin
    Xu, Huijun
    Cui, Jiazhen
    Huang, Simao
    Wei, Guoqing
    Chang, Alex H.
    Huang, He
    Hu, Yongxian
    BLOOD, 2024, 144 : 2819 - 2819
  • [23] Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
    Roddie, Claire
    Lekakis, Lazaros J.
    Marzolini, Maria A. V.
    Ramakrishnan, Aravind
    Zhang, Yiyun
    Hu, Yanqing
    Peddareddigari, Vijay G. R.
    Khokhar, Nushmia
    Chen, Robert
    Basilico, Silvia
    Raymond, Meera
    Vargas, Frederick Arce
    Duffy, Kevin
    Brugger, Wolfram
    O'Reilly, Maeve A.
    Wood, Leigh
    Linch, David C.
    Peggs, Karl S.
    Bachier, Carlos
    Budde, Elizabeth Lihua
    Batlevi, Connie Lee
    Bartlett, Nancy
    Irvine, David
    Tholouli, Eleni
    Osborne, Wendy
    Ardeshna, Kirit M.
    Pule, Martin A.
    BLOOD, 2023, 141 (20) : 2470 - 2482
  • [24] Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
    Wang, Yu
    Xue, Yu-juan
    Zuo, Ying-xi
    Jia, Yue-ping
    Lu, Ai-dong
    Zeng, Hui-min
    Zhang, Le-ping
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [25] Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation
    Liu, Shuangyou
    Deng, Biping
    Yin, Zhichao
    Lin, Yuehui
    An, Lihong
    Liu, Dan
    Pan, Jing
    Yu, Xinjian
    Chen, Bingzhen
    Wu, Tong
    Chang, Alex H.
    Tong, Chunrong
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : 671 - 679
  • [26] Dual targeting of CD19 and CD22 against B-ALL a novel-sensitivity aCD22 CAR
    Kokalaki, Evangelia
    Ma, Biao
    Ferrari, Mathieu
    Grothier, Thomas
    Hazelton, Warren
    Manzoor, Somayya
    Costu, Eren
    Taylor, Julia
    Bulek, Anna
    Srivastava, Saket
    Gannon, Isaac
    Jha, Ram
    Gealy, Rosalind
    Stanczuk, Lukas
    Rizou, Tatiana
    Robson, Mathew
    El-Kholy, Mohamed
    Baldan, Vania
    Righi, Matteo
    Sillibourne, James
    Thomas, Simon
    Onuoha, Shimobi
    Cordoba, Shaun
    Pule, Martin
    MOLECULAR THERAPY, 2023, 31 (07) : 2089 - 2104
  • [27] First-Line Consolidation Therapy with CD19/CD22 Bispecific CAR-T Cells for MRD Positive B-ALL Maybe Feasible
    Song, Xianmin
    BLOOD, 2022, 140 : 12749 - 12749
  • [28] Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/Refractory ALL Patients
    Tang, Xiaowen
    Kang, Liqing
    Qi, Wei
    Cui, Wei
    Dai, Haiping
    Li, Zheng
    Yin, Jia
    Qu, Changju
    Xu, Ting
    Zhu, Xiaming
    Yu, Lei
    Wu, Depei
    BLOOD, 2019, 134
  • [29] CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
    Spiegel, Jay Y.
    Patel, Shabnum
    Muffly, Lori
    Hossain, Nasheed M.
    Oak, Jean
    Baird, John H.
    Frank, Matthew J.
    Shiraz, Parveen
    Sahaf, Bita
    Craig, Juliana
    Iglesias, Maria
    Younes, Sheren
    Natkunam, Yasodha
    Ozawa, Michael G.
    Yang, Eric
    Tamaresis, John
    Chinnasamy, Harshini
    Ehlinger, Zach
    Reynolds, Warren
    Lynn, Rachel
    Rotiroti, Maria Caterina
    Gkitsas, Nikolaos
    Arai, Sally
    Johnston, Laura
    Lowsky, Robert
    Majzner, Robbie G.
    Meyer, Everett
    Negrin, Robert S.
    Rezvani, Andrew R.
    Sidana, Surbhi
    Shizuru, Judith
    Weng, Wen-Kai
    Mullins, Chelsea
    Jacob, Allison
    Kirsch, Ilan
    Bazzano, Magali
    Zhou, Jing
    Mackay, Sean
    Bornheimer, Scott J.
    Schultz, Liora
    Ramakrishna, Sneha
    Davis, Kara L.
    Kong, Katherine A.
    Shah, Nirali N.
    Qin, Haiying
    Fry, Terry
    Feldman, Steven
    Mackall, Crystal L.
    Miklos, David B.
    NATURE MEDICINE, 2021, 27 (08) : 1419 - +
  • [30] A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
    Fergusson, Nathan J.
    Adeel, Komal
    Kekre, Natasha
    Atkins, Harold
    Hay, Kevin A.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345